Endoscopic incisional therapy

  • 文章类型: Journal Article
    背景:研究已经评估了内镜下切口治疗(EIT)对良性吻合口狭窄的疗效。我们进行了系统评价和荟萃分析,以评估食管切除术或胃切除术后EIT狭窄的复发。
    方法:对数据库进行了系统搜索,直到4月2日,2023年,在与研究团队一起选择关键搜索词后。纳入标准包括因食管切除术或胃切除术后良性吻合口狭窄而接受EIT的人类参与者,年龄≥18岁,n≥5岁。我们的主要结果是与扩张相比,接受EIT治疗的患者狭窄复发的发生率。我们的次要结果是EIT后无狭窄持续时间和不良事件发生率。采用Mantel-Haenszel随机效应模型对RevMan5.4.1进行Meta分析。用漏斗图和Egger检验评估发表偏差。
    结果:共有2550项独特的初步研究进行了摘要和标题筛选。这导致33项研究进行了全文回顾,其中5项研究符合纳入标准。荟萃分析显示,与扩张相比,接受EIT的患者总体狭窄复发的几率降低(OR0.35,95%CI0.13-0.92,p=0.03;I2=71%),而未治疗狭窄的复发几率降低(OR0.32,95%CI0.17-0.59,p=0.0003;I2=0%)。复发狭窄的狭窄复发几率没有显着差异(OR0.63,95%CI0.12-3.28,p=0.58;I2=81%)。荟萃分析显示,与扩张相比,接受EIT的患者的无复发持续时间显着增加(MD42.76,95%CI12.41-73.11,p=0.006)。
    结论:目前的数据表明,在初治吻合口狭窄中,EIT与狭窄复发几率降低相关。大,需要前瞻性研究来描述EIT的安全性,解决出版偏见,并探索难治性狭窄的多模式疗法。
    BACKGROUND: Studies have evaluated the efficacy of endoscopic incisional therapy (EIT) for benign anastomotic strictures. We performed a systematic review and meta-analysis to evaluate stricture recurrence after EIT following esophagectomy or gastrectomy.
    METHODS: A systematic search of databases was performed up to April 2nd, 2023, after selection of key search terms with the research team. Inclusion criteria included human participants undergoing EIT for a benign anastomotic stricture after esophagectomy or gastrectomy, age ≥ 18, and n ≥ 5. Our primary outcome was the incidence of stricture recurrence among patients treated with EIT compared to dilation. Our secondary outcome was the stricture-free duration after EIT and rate of adverse events. Meta-analysis was performed with RevMan 5.4.1 using a Mantel-Haenszel random-effects model. Publication bias was evaluated with funnel plots and the Egger test.
    RESULTS: A total of 2550 unique preliminary studies underwent screening of abstracts and titles. This led to 33 studies which underwent full-text review and five studies met the inclusion criteria. Meta-analysis revealed reduced odds of overall stricture recurrence (OR 0.35, 95% CI 0.13-0.92, p = 0.03; I2 = 71%) and reduced odds of stricture recurrence among naïve strictures (OR 0.32, 95% CI 0.17-0.59, p = 0.0003; I2 = 0%) for patients undergoing EIT compared to dilation. There was no significant difference in the odds of stricture recurrence among recurrent strictures (OR 0.63, 95% CI 0.12-3.28, p = 0.58; I2 = 81%). Meta-analysis revealed a significant increase in the recurrence-free duration (MD 42.76, 95% CI 12.41-73.11, p = 0.006) among patients undergoing EIT compared to dilation.
    CONCLUSIONS: Current data suggest EIT is associated with reduced odds of stricture recurrence among naïve anastomotic strictures. Large, prospective studies are needed to characterize the safety profile of EIT, address publication bias, and to explore multimodal therapies for refractory strictures.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    OBJECTIVE: Congenital esophageal stenosis (CES) is an inborn condition of the esophagus that can be refractory to endoscopic dilation. Surgical intervention is not curative, with patients experiencing frequent ongoing need for therapy for anastomotic stricture postoperatively. We hypothesized that novel methods of endoscopic CES management including endoscopic incisional therapy (EIT) would lead to less surgical intervention.
    METHODS: We retrospectively reviewed the medical records of all patients with CES treated by our tertiary care center who had at least one endoscopy between July 2007 and July 2019. Statistical comparison of cohorts who underwent advanced endoscopic therapy involving EIT versus traditional endoscopic therapy with balloon dilation was performed. Primary outcome measure was need for surgical intervention.
    RESULTS: Thirty-six patients with CES met inclusion criteria. Thirty-four ever had at least one endoscopic intervention such as balloon dilation, steroid injection, stenting, and/or endoscopic incisional therapy (EIT) at their CES. Esophageal vacuum assisted closure (EVAC) was used for treatment or prevention of esophageal leak. Odds of surgical intervention were significantly lower in the group who received therapeutic endoscopy with EIT (odds ratio (OR) 0.1; p = 0.007). Clinical feeding outcomes were similar in the endoscopic and surgical management groups. Odds of complications after therapeutic endoscopies involving EIT were significantly greater than those without EIT (odds ratio 6.39; 95% confidence interval (2.34, 17.44); p < 0.001), though our rates of esophageal leak significantly decreased over time as our use of EVAC increased (Spearman\'s ρ = -0.884; p = 0.004).
    CONCLUSIONS: Complementary endoscopic techniques such as EIT broaden the toolbox of the treating physician and may allow for avoidance of surgery in CES.
    METHODS: Level III.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    目的:本文介绍了作者对食管扩张的研究方法。它为扩张应用于特定类型的食管狭窄病变提供了量身定制的方法。
    结果:在炎性狭窄患者中,最近的研究证实了治疗潜在炎症的重要性,以降低复发率。本文回顾了一些被建议用于治疗难治性良性食管狭窄的新技术。包括切口治疗,支架,或注射类固醇或抗纤维化药物。治疗食管狭窄的内窥镜医师必须熟悉扩张工具以及如何将其最佳应用于特定类型的狭窄病变。如果存在炎症,有效的治疗除了狭窄病变的机械扩张外,还需要治疗炎症过程。治疗难治性良性食管狭窄的新方法的对照试验是有限的,并且对于确定疗效是必要的。
    OBJECTIVE: This paper presents the author\'s approach to esophageal dilation. It offers a tailored approach to the application of dilation to specific types of esophageal stenotic lesions.
    RESULTS: In patients with inflammatory stricture, recent studies confirm the importance of treating the underlying inflammatory condition in order to decrease the rate of recurrence. The paper reviews some of the novel techniques that have been suggested for the treatment of refractory benign esophageal strictures, including incisional therapy, stenting, or the injection steroids or antifibrotic agents. The endoscopist who treats esophageal strictures must be familiar with the tools of the dilation and how they are best applied to specific types of stenotic lesions. If inflammation is present, effective management requires treatment of the inflammatory process in addition to mechanical dilation of the stenotic lesion. Controlled trials of novel approaches to treatment of refractory benign esophageal strictures are limited and will be necessary to determine efficacy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Benign esophageal strictures refractory to the conventional balloon or bougie dilatation may be subjected to various adjunctive modes of therapy, one of them being endoscopic incisional therapy (EIT). A proper delineation of the stricture anatomy is a prerequisite. A host of electrocautery and mechanical devices may be used, the most common being the use of needle knife, either standard or insulated tip. The technique entails radial incision and cutting off of the stenotic rim. Adjunctive therapies, to prevent re-stenosis, such as balloon dilatation, oral or intralesional steroids or argon plasma coagulation can be used. The common strictures where EIT has been successfully used are Schatzki\'s rings (SR) and anastomotic strictures (AS). Short segment strictures (< 1 cm) have been found to have the best outcome. When compared with routine balloon dilatation, EIT has equivalent results in treatment naïve cases but better long term outcome in refractory cases. Anecdotal reports of its use in other types of strictures have been noted. Post procedure complications of EIT are mild and comparable to dilatation therapy. As of the current evidence, incisional therapy can be used for management of refractory AS and SR with relatively short stenosis (< 1 cm) with good safety profile and acceptable long term patency.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    The reported incidence of anastomotic stricture after esophageal atresia repair has varied in case series from as low as 9% to as high as 80%. The cornerstone of esophageal stricture treatment is dilation with either balloon or bougie. The goal of esophageal dilation is to increase the luminal diameter of the esophagus while also improving dysphagia symptoms. Once a stricture becomes refractory to esophageal dilation, there are several treatment therapies available as adjuncts to dilation therapy. These therapies include intralesional steroid injection, mitomycin C, esophageal stent placement, and endoscopic incisional therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号